Follow-On Biologics Bill’s Prospects Are Uncertain, Waxman Staffer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Busy House committee schedule and “fractured” Senate will make reaching consensus a challenge, Ann Witt says, but potential inclusion of FOBs into health reform bill is “wildcard.”
You may also be interested in...
FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key
The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].
FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key
The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].
Kennedy's Follow-On Biologics Revisions Add Anti-"Evergreening" Language
Restrictions are similar to those in Rep. Waxman's bill, but less specific.